Look up one drug

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Jamp Gabapentin Capsules · DIN 02535254 Manufacturer: Jamp Pharma Corporation; listing date 2024-04-30 Health Canada: Marketed since 2024-03-07 · brand JAMP GABAPENTIN CAPSULES · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 300 MG · company Jamp pharma corporation · schedule Prescription

DIN 02535254: Jamp Gabapentin Capsules Raw flags: sec3=Y Item: 281200063; group id 430; item number 1071; lccId None; manufacturer id JPC Source form: Cap; strength: 300mg Recorded listing: General benefit Source prices (unrounded): $0.1012; ministry $0.1012 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02535254 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102412

Interchangeable products

AG-Gabapentin · DIN 02477920 · $0.1012 Apo-Gabapentin · DIN 02244305 · $0.1012 Auro-Gabapentin · DIN 02321211 · $0.1012 Co Gabapentin · DIN 02256150 · $0.1012 Gabapentin · DIN 02246315 · $0.1012 Gabapentin · DIN 02353253 · $0.1012 Gabapentin Capsules USP · DIN 02416859 · $0.1012 Jamp-Gabapentin · DIN 02361485 · $0.1012 Mar-Gabapentin · DIN 02391481 · $0.1012 Mint-Gabapentin · DIN 02408899 · $0.1012 NRA-Gabapentin · DIN 02550024 · $0.1012 Neurontin · DIN 02084279 · $0.1012 PMS-Gabapentin · DIN 02243447 · $0.1012 Ran-Gabapentin · DIN 02319063 · $0.1012 Teva-Gabapentin · DIN 02244514 · $0.1012

Shortage status: not checked (no credentials)